Takahiro Kambara, Rei Shibata, Yuusuke Sakamoto, Teruhiro Sakaguchi, Hiroyuki Osanai, Yoshihito Nakashima, Hiroshi Asano, Toyoaki Murohara, Masayoshi Ajioka
OBJECTIVE: Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors are a new class of anti-anemia agents. We retrospectively evaluated the safety and efficacy of HIF-PH inhibitors in patients with heart failure (HF) complicated by anemia associated with chronic kidney disase. HIF-PH inhibitor treatment was initiated in 32 patients with chronic HF complicated by renal anemia and were followed up for 3 months. RESULTS: Hematocrit and hemoglobin levels markedly improved 3 months after HIF-PH inhibitor treatment...
March 1, 2024: BMC Research Notes